Venous thromboembolism

Affiliations

¹ Oxford University Hospitals NHS Foundation Trust, NIHR Oxford Biomedical Research Centre,  Oxford, UK.
² Hampshire Hospitals and Salisbury NHS Foundation Trusts, Basingstoke, UK.
³ King's College Hospital NHS Foundation Trust, London, UK.

Comment

Susan Shapiro et al. Clin Med (Lond). 2019 May.

. 2019 May;19(3):262.

doi: 10.7861/clinmedicine.19-3-262a.

¹ Oxford University Hospitals NHS Foundation Trust, NIHR Oxford Biomedical Research Centre,  Oxford, UK.
² Hampshire Hospitals and Salisbury NHS Foundation Trusts, Basingstoke, UK.
³ King's College Hospital NHS Foundation Trust, London, UK.

No abstract available

Comment on

Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism in medical inpatients.
Stansby G, Donald I. Stansby G, et al. Clin Med (Lond). 2019 Mar;19(2):100-103. doi: 10.7861/clinmedicine.19-2-100. Clin Med (Lond). 2019. PMID: 30872288 Free PMC article. No abstract available.

1. Stansby G, Donald I. Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism in medical inpatients. Clin Med 2019;19:100–3. - PMC - PubMed
1. National Institute for Health and Care Excellence Venous thromboembolism in over 16s; reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline [NG89]. London: NICE, 2018. www.nice.org.uk/guidance/ng89 [Accessed 21 March 2019]. - PubMed
1. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med 1999;341:793–800. - PubMed
1. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874–9. - PubMed